Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update
Authors: Elizabeth J. Phillips
Chonlaphat Sukasem
Michelle Whirl-Carrillo
Daniel J. Müller
Henry M. Dunnenberger
Wasun Chantratita
Barry Goldspiel
Yuan Tsong Chen
Bruce C. Carleton
Alfred L. George
Taisei Mushiroda
Teri Klein
Roseann S. Gammal
Munir Pirmohamed
Duke University Medical Center
NorthShore University HealthSystem
Vanderbilt University Medical Center
University of Liverpool
St. Jude Children's Research Hospital
Academia Sinica Taiwan
University of Toronto
NIH Clinical Center
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Centre for Addiction and Mental Health
Northwestern University Feinberg School of Medicine
Stanford University
The University of British Columbia
MCPHS University
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Apr-2018
Citation: Clinical Pharmacology and Therapeutics. Vol.103, No.4 (2018), 574-581
Abstract: © 2018 American Society for Clinical Pharmacology and Therapeutics The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.
ISSN: 15326535
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.